Comparison of changes in %FMD before and after treatment in each group.

<p>Comparison of changes in %FMD before and after treatment in each group.</p

CONSORT flow diagram.

<p>CONSORT flow diagram.</p

Clinical characteristics of the study population.

<p>Clinical characteristics of the study population.</p

Comparison of individual changes of FMD before and after administration of liraglutide and glargine.

<p>White circles are mean ± SD.</p

Comparison of the effects on endothelial function and clinical and biochemical parameters between liraglutide and glargine.

<p>* Data were obtained in 30 patients (Liraglutide N = 15, Glargine N = 15).</p><p>** Data were obtained in 23 patients (Liraglutide N = 12, Glargine N = 11)</p><p>BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FMD, flow-mediated dilatation; cSBP, centric systolic blood pressure; TPRI, total peripheral resistance index; LF, low frequency; HF, high frequency; RRI, R-R interval; RHI, reactive hyperemia index; FPG, fasting blood glucose; SOD, superoxide dismutase; PAI-1, plasminogen activator inhibitor-1; NT-proBNP, N terminal prohormone of brain natriuretic peptide; TNF-α, tumor necrosis factor alpha; hsCRP, high-sensitivity C-reactive protein; d-ROMs, reactive oxygen metabolites-derived compounds; BAP, biological antioxidant potential. Values are mean change from baseline mean (95%CI).</p><p>^† Values were analyzed using Wilcoxon signed test since the normality was rejected in these variables.</p><p>Comparison of the effects on endothelial function and clinical and biochemical parameters between liraglutide and glargine.</p

Relationship between the changes in %FMD and other metabolic parameters pre- and post-treatment with liraglutide or glargine.

<p>BMI, body mass index; CPR, C-peptide; cSBP, centric systolic blood pressure; PAI-1, plasminogen activator inhibitor-1; d-ROMs, reactive oxygen metabolites-derived compounds.</p><p>* Correlation coefficient for Pearson’s collection analysis,</p><p>** correlation coefficient for Spearman’s rank-correction.</p><p>Relationship between the changes in %FMD and other metabolic parameters pre- and post-treatment with liraglutide or glargine.</p

Comparison of changes in %FMD before and after treatment in each group.

<p>Values are expressed as mean ± SD or the least square means (95% CI). The least square means were calculated by ANCOVA adjusted for baseline FMD.</p><p>Comparison of changes in %FMD before and after treatment in each group.</p

Clinical characteristics of the study population.

<p>FPG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; DPP-4, dipeptidyl peptidase-4. Values are mean　±　SD or median (interquartile). <i>P</i> value of liraglutide vs glargine treated groups.</p><p>* Mann—Whitney U test was applied to body mass index.</p><p>Clinical characteristics of the study population.</p

Comparison of individual changes of FMD before and after administration of liraglutide and glargine.

<p>White circles are mean ± SD.</p

CONSORT Flowchart Participant Flow and Recruitment.

<p>CONSORT Flowchart Participant Flow and Recruitment.</p